Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis

被引：13

作者：

Arihiro K. ^{[1
]}

Kaneko M. ^{[1
]}

Fujii S. ^{[1
]}

Inai K. ^{[1
]}

机构：

[1] Second Department of Pathology, Hiroshima University, School of Medicine, Minami-ku, Hiroshima 734-8551

来源：

Breast Cancer | 1998年 / 5卷 / 2期

关键词：

Breast carcinoma; CD31/PECAM-1; CD9; VEGF/VPF;

D O I：

10.1007/BF02966685

中图分类号：

学科分类号：

摘要：

Immunohistochemical staining for CD9, CD31 and vascular endothelial growth factor (VEGF) was performed in breast carcinoma specimens. CD9 was expressed in the membrane of carcinoma cells in 61 of 93 cases (67%), CD31 in the membrane of carcinoma cells in 23 of 86 cases (27%), and VEGF in the cytoplasm of carcinoma cells in 26 of 86 cases (30%). The expression of CD9, CD31 and VEGF did not singly correlate with any clinicopathological factors. However, a loss of CD9 with concurrent expression of CD31 or VEGF in the invasive component showed a slight correlation with lymph node metastasis. These findings suggest that the potential for metastatic spread to lymph nodes in breast carcinoma may be synergically affected by various factors.

引用

页码：131 / 138

页数：7

共 44 条

[1]

Liotta L.A., Steeg P.S., Stetler-Stevenson W.G., Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation, Cell, 64, 2, pp. 327-336, (1991)

[2]

Narita T., Funahashi H., Satoh Y., Watanabe T., Sakamoto J., Takagi H., Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer, Cancer, 71, 10, pp. 3044-3053, (1993)

[3]

Horejsi V., Vlcek C., Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53 and CD63, FEBS Lett, 288, pp. 1-4, (1991)

[4]

Boucheix C., Benoit P., CD9 antigen

[5]

Will platelet physiology help to explain the function of a surface molecule during hemopoietic differentiation?, Nouv Rev Fr Hematol, 30, pp. 201-202

[6]

Forsyth K.D., Anti-CD9 antibodies augment neutrophil adherence to endothelium, Immunology, 72, pp. 292-296, (1991)

[7]

Boucheix C., Benoit P., Frachet P., Et al., Molecular cloning of the CD9 antigen, J Biol Chem, 266, pp. 117-122, (1991)

[8]

Miyake M., Koyama M., Seno M., Et al., Identification of the motility-related protein (MRP-1), recognized by monoclonal antibody M31-15, which inhibits cell motility, J Exp Med, 174, pp. 1347-1354

[9]

Ikeyama S., Koyama M., Yamaoko M., Sasada R., Miyake M., Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA, Journal of Experimental Medicine, 177, 5, pp. 1231-1237, (1993)

[10]

Higashiyama S., Iwamoto R., Goishi K., Et al., The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the Membraneanchored heparin-binding EGF-like growth factor, J Cell Biol, 128, pp. 929-938, (1995)

← 1 2 3 4 5 →